Oralair

Grass pollen allergen extract, the active ingredient in Oralair, is a allergen immunotherapy presented as a sublingual tablet for sublingual use. It is indicated for the prevention and reduction of symptoms of seasonal allergic rhinitis caused by grass pollen in patients with confirmed sensitivity.

GNH USA supplies Oralair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant distribution across multiple regions, ensuring product integrity from manufacturing to end‑user.

Oralair is used in allergen immunotherapy to modify the immune response to grass pollen allergens.

Seasonal allergic rhinitis (grass pollen): reduces frequency and intensity of nasal symptoms. Allergic rhinoconjunctivitis (grass pollen): improves both nasal and ocular symptoms. Grass pollen allergy in children (5‑17 years): provides long‑term tolerance when administered as prescribed.

Oralair may cause local and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Oral itching or tingling. - Throat irritation or mild swelling. - Mild gastrointestinal discomfort. - Headache. - Transient local edema. - Mild urticaria.

Serious or Rare Side Effects: - Anaphylaxis or severe systemic allergic reaction. - Severe oral or facial swelling that impairs breathing. - Respiratory distress or bronchospasm. - Angioedema. - Severe urticaria with systemic involvement.

Before prescribing Oralair, clinicians should consider the following precautions to ensure safe use.

Assess patient history: confirm documented grass pollen allergy before initiation. Avoid use in uncontrolled asthma: ensure asthma is well‑controlled prior to treatment. Monitor early treatment phase: observe for local reactions during the first week of therapy. Do not combine with other allergen immunotherapies unless directed by a specialist. Pregnancy and lactation: use only if the potential benefit outweighs the unknown risk. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Oralair can interact with certain medications and other immunotherapies; awareness of these interactions helps manage risk.

Major Interactions (Avoid): - Beta‑blockers: may reduce the effectiveness of emergency epinephrine in case of severe allergic reaction. - ACE inhibitors: increase the risk of angioedema when combined with allergen exposure.

Moderate Interactions (Monitor Closely): - Systemic antihistamines: may mask early signs of local allergic reactions. - Immunosuppressants (e.g., methotrexate, azathioprine): may diminish the therapeutic response to immunotherapy. - Oral corticosteroids: can suppress the intended immune modulation of the treatment.